BOSTON SCIENTIFIC ($BSX) posted quarterly earnings results for Q4 2025 on Wednesday, February 4th. The company reported earnings of $0.80 per share, beating estimates of $0.79 by $0.01. The company also reported revenue of $5,286,000,000, missing estimates of $5,333,063,569 by $-47,063,569.
You can see Quiver Quantitative's $BSX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BOSTON SCIENTIFIC Insider Trading Activity
BOSTON SCIENTIFIC insiders have traded $BSX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $BSX stock by insiders over the last 6 months:
- JOSEPH MICHAEL FITZGERALD (EVP & Group Pres, Cardiology) has made 0 purchases and 7 sales selling 150,000 shares for an estimated $15,168,080.
- MICHAEL F MAHONEY (Chairman, President & CEO) has made 0 purchases and 2 sales selling 160,901 shares for an estimated $15,043,394.
- ELLEN M ZANE has made 0 purchases and 3 sales selling 25,782 shares for an estimated $2,573,877.
- ARTHUR C BUTCHER (EVP& Grp Pres, MedSurg & APAC) sold 17,313 shares for an estimated $1,758,188
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BOSTON SCIENTIFIC Hedge Fund Activity
We have seen 869 institutional investors add shares of BOSTON SCIENTIFIC stock to their portfolio, and 786 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 17,996,024 shares (-55.1%) from their portfolio in Q3 2025, for an estimated $1,756,951,823
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 9,206,700 shares (+72.2%) to their portfolio in Q3 2025, for an estimated $898,850,121
- FMR LLC removed 8,832,876 shares (-8.2%) from their portfolio in Q3 2025, for an estimated $862,353,683
- PARNASSUS INVESTMENTS, LLC added 6,868,459 shares (+42978.9%) to their portfolio in Q3 2025, for an estimated $670,567,652
- POLEN CAPITAL MANAGEMENT LLC added 5,598,286 shares (+inf%) to their portfolio in Q3 2025, for an estimated $546,560,662
- VOYA INVESTMENT MANAGEMENT LLC removed 4,362,310 shares (-49.9%) from their portfolio in Q3 2025, for an estimated $425,892,325
- UBS GROUP AG added 4,304,984 shares (+40.7%) to their portfolio in Q4 2025, for an estimated $410,480,224
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BOSTON SCIENTIFIC Government Contracts
We have seen $22,938,881 of award payments to $BSX over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION: $1,260,000
- Y90 GLASS MICROSPHERES: $1,197,000
- Y90 THERASPHERE: $1,155,000
- VAPAHCS THERASPHERE Y90 RADIOPHARMACEUTICALS: $954,240
- THERASPHERE YTTIRUM-90 (Y-90) GLASS: $833,910
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BOSTON SCIENTIFIC Congressional Stock Trading
Members of Congress have traded $BSX stock 10 times in the past 6 months. Of those trades, 4 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $BSX stock by members of Congress over the last 6 months:
- SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $30,000 on 11/18, 10/17 and 1 sale worth up to $15,000 on 12/24.
- SENATOR JOHN BOOZMAN sold up to $15,000 on 12/17.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
- REPRESENTATIVE KEVIN HERN sold up to $50,000 on 10/28.
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BOSTON SCIENTIFIC Analyst Ratings
Wall Street analysts have issued reports on $BSX in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/17/2025
- BTIG issued a "Buy" rating on 11/21/2025
- Truist Securities issued a "Buy" rating on 10/23/2025
- UBS issued a "Buy" rating on 10/23/2025
- Needham issued a "Buy" rating on 10/17/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Baird issued a "Outperform" rating on 10/01/2025
To track analyst ratings and price targets for BOSTON SCIENTIFIC, check out Quiver Quantitative's $BSX forecast page.
BOSTON SCIENTIFIC Price Targets
Multiple analysts have issued price targets for $BSX recently. We have seen 14 analysts offer price targets for $BSX in the last 6 months, with a median target of $126.5.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $124.0 on 02/03/2026
- Suraj Kalia from Oppenheimer set a target price of $100.0 on 01/16/2026
- Richard Newitter from Truist Securities set a target price of $120.0 on 12/18/2025
- William Plovanic from Canaccord Genuity set a target price of $131.0 on 12/17/2025
- Shagun Singh from RBC Capital set a target price of $130.0 on 12/17/2025
- Marie Thibault from BTIG set a target price of $132.0 on 11/21/2025
- Larry Biegelsen from Wells Fargo set a target price of $125.0 on 10/23/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
